TELO vs. PAHC, LYEL, SAGE, ANAB, AVBP, HROW, DNTH, ABUS, MLYS, and SLN
Should you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include Phibro Animal Health (PAHC), Lyell Immunopharma (LYEL), Sage Therapeutics (SAGE), AnaptysBio (ANAB), ArriVent BioPharma (AVBP), Harrow (HROW), Dianthus Therapeutics (DNTH), Arbutus Biopharma (ABUS), Mineralys Therapeutics (MLYS), and Silence Therapeutics (SLN). These companies are all part of the "pharmaceutical preparations" industry.
Phibro Animal Health (NASDAQ:PAHC) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment, earnings and community ranking.
Phibro Animal Health presently has a consensus target price of $14.75, indicating a potential downside of 16.34%. Given Telomir Pharmaceuticals' higher probable upside, equities analysts clearly believe Phibro Animal Health is more favorable than Telomir Pharmaceuticals.
Phibro Animal Health has higher revenue and earnings than Telomir Pharmaceuticals.
In the previous week, Telomir Pharmaceuticals had 1 more articles in the media than Phibro Animal Health. MarketBeat recorded 3 mentions for Telomir Pharmaceuticals and 2 mentions for Phibro Animal Health. Telomir Pharmaceuticals' average media sentiment score of 0.81 beat Phibro Animal Health's score of 0.30 indicating that Phibro Animal Health is being referred to more favorably in the media.
Phibro Animal Health received 305 more outperform votes than Telomir Pharmaceuticals when rated by MarketBeat users.
Phibro Animal Health has a net margin of 1.32% compared to Phibro Animal Health's net margin of 0.00%. Telomir Pharmaceuticals' return on equity of 17.11% beat Phibro Animal Health's return on equity.
99.3% of Phibro Animal Health shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Phibro Animal Health beats Telomir Pharmaceuticals on 11 of the 12 factors compared between the two stocks.
Get Telomir Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Telomir Pharmaceuticals Competitors List
Related Companies and Tools
